Quetiapine Fumarate Extended-release Tablet Formulation Design Using Artificial Neural Networks

Basit Öğe Kaydı
dc.contributor.authorOzcelik, Esher
dc.contributor.authorMesut, Burcu
dc.contributor.authorAksu, Buket
dc.contributor.authorOzsoy, Yildiz
dc.date.accessioned2025-02-06T17:58:19Z
dc.date.available2025-02-06T17:58:19Z
dc.date.issued2017
dc.departmentAltınbaş Üniversitesien_US
dc.description.abstractObjectives: This design study was implemented within the scope of the quality by design approach, which included the International Conference on Harmonization guidelines. We evaluated the quality of a modified-release tablet formulation of quetiapine fumarate, which was designed using artificial neural networks (ANN), and determined a new formulation that was similar to the reference product. Materials and Methods: Twelve different formulations were produced and tested. The reference product's results and our experimental results were used as outputs for the training of the ANN programs of Intelligensys Ltd. Results: Dissolution tests were performed with the new formulation (F13) suggested by the INForm V.4 ANN program in three different pHs of the gastrointestinal system. The compliance of this formulation was confirmed by comparing the results with an f2 similarity test. Conclusion: Use of these programs supports research and development processes with multiple evaluation methods and alternative formulations may be determined faster and at lower cost.en_US
dc.description.sponsorshipResearch Fund of the Istanbul University [26586]en_US
dc.description.sponsorshipThis study was supported by Research Fund of the Istanbul University project number: 26586. An application for a patent has been made to the Turkish Patent Institute using the results of this study (Application number: TR 2013-G-316804).en_US
dc.identifier.doi10.4274/tjps.97720
dc.identifier.endpage221en_US
dc.identifier.issn1304-530X
dc.identifier.issue3en_US
dc.identifier.pmid32454616
dc.identifier.scopus2-s2.0-85034989862
dc.identifier.scopusqualityQ2en_US
dc.identifier.startpage213en_US
dc.identifier.trdizinid244208
dc.identifier.urihttps://doi.org/10.4274/tjps.97720
dc.identifier.urihttps://search.trdizin.gov.tr/tr/yayin/detay/244208
dc.identifier.urihttps://hdl.handle.net/20.500.12939/5174
dc.identifier.volume14en_US
dc.identifier.wosWOS:000417379400001
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakTR-Dizin
dc.indekslendigikaynakPubMed
dc.language.isoenen_US
dc.publisherTurkish Pharmacists Assocen_US
dc.relation.ispartofTurkish Journal of Pharmaceutical Sciencesen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.snmzKA_WOS_20250206
dc.subjectQuetiapine fumarateen_US
dc.subjectquality by designen_US
dc.subjectartificial neural networksen_US
dc.subjectneuro-fuzzy logicen_US
dc.subjectextended-release tabletsen_US
dc.subjectwet granulationen_US
dc.titleQuetiapine Fumarate Extended-release Tablet Formulation Design Using Artificial Neural Networksen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu
TR-Dizin İndeksli Yayınlar Koleksiyonu